Skip to main content

Table 9 The combined synergizing effects of Mcl1-inhibitors against selected cancer and cell types

From: BH3-mimetics: recent developments in cancer therapy

Agents

Cancer

Cell Type

Combined

Ref

A1210477

AML

THP-1 U937

venetoclax

[337]

A1210477

Breast

MDA-MB-231 cells

TRAIL

[338]

A1210477

Cervical

SiHa and CaSki

navitoclax

[139]

A1210477

CML

K562, K562/R

EE-84

[339]

A1210477

CRC

RKO, HT29, A375

cobimetinib

[340]

A1210477

DLBCL

U-2946

navitoclax

[341]

A1210477

PC, GC, NSCLC, MM

BxPC-3, EJ-1, H23, and OPM-2

navitoclax

[70]

A1210477

HNSCC

PCI15B, Detroit 562, MDA686LN, and HN30

navitoclax

[342]

A1210477

nHL

SU-DHL-4, WSU-NHL, WSU-DLCL2, KARPAS-422

venetoclax

[343]

AMG-176

CLL

Patient samples (5)

venetoclax

[344]

AZD-5991

AML

OCI-AML3 and MCL-1-OE Molm13 and MV4–11

venetoclax

[345]

AZD5991

MM

NCI-H929

bortezomib, venetoclax

[73]

GDC-0941

Breast

MDA-MB-231, SKBR3

ABT-737

[346]

Mim1

Glioblastoma

U87mg

temozolomide

[347]

Mim1

Melanoma

C32 melanoma cells

dacarbazine

[348]

Mim1

MM

Colo829

dacarbazine

[349]

S63845

AML

OCI-AML3, MOLM-13, OCI-AML2

trametinib/HDM201

[350]

S63845

AML

Primary samples

venetoclax

[351]

S63845

AML

MOML-13, SKM-1,

trametinib

[352]

S63845

AML

Cell lines and primary cells

venetoclax

[353]

S63845

Breast

SK-BR-3

docetaxel, trastuzumab, lapatinib

[354]

S63845

CRC

HCT116

regorafenib

[355]

S63845

Mantle cell lymphoma

Patient-derived xenografts

venetoclax

[356]

S63845

Melanoma

Patient samples

navitoclax

[357]

S63845

Melanoma

MeWo

TRAIL resistance

[358]

S63845

Myeloma

U266 xenograft

venetoclax

[359]

S63845

MM

MOL-P8, OPM-2, NCI-H929

venetoclax, bortezomib

[360]

S63845

MM

RPMI-8226 xenograft

venetoclax

[361]

S63845

Nasopharyngeal carcinoma

CNE-2, 5-8F

venetoclax

[293]

S63845

T-ALL

Zebrafish T-ALL cells

venetoclax

[304]

VU661013

AML

MV-4-11, AML-001/2, patient xenografts

venetoclax

[76]

VU661013

Breast

HCC1428, MCF7, T47D

navitoclax

[362]

  1. The therapeutic types (Agents) are highlighted in bold (left column) and their corresponding studies referenced in the column on the right (Ref). Abbreviations: CML Chronic Myelogenous Leukemia, CRC Colorectal cancer, DLBCL Diffuse large B-Cell Lymphoma, PC Prostate Cancer, GC Gastric Cancer, NSCLC Non-small cell lung cancer, MM Multiple myeloma, HNSCC Head and Neck Squamous Cell Carcinoma, nHL Non-Hodgkin’s Lymphoma, CLL Chronic lymphocytic leukemia, AML Acute Myelogenous Lymphoma, T-ALL T-cell acute lymphoblastic leukemia